Approximately one in four prescription-only medicinal products are paid out of pocket by EU patients, whereas the rest is funded by the healthcare system or compulsory health insurances via reimbursement procedures. For reimbursed products, the price setting process for new pharmaceutical products are clearly defined across EU markets with information being readily accessible.
There is a lack of published information concerning the pricing processes for non-reimbursed prescription-only medicinal products, therefore, the objective of this research was to determine the national price submission procedures across Europe required for launch and patient access for non-reimbursed prescription-only medicinal products.
Read our findings here….(Achieving faster product launch)